• Produktbild: Sudden Cardiac Death and Congestive Heart Failure: Diagnosis and Treatment
  • Produktbild: Sudden Cardiac Death and Congestive Heart Failure: Diagnosis and Treatment
Band 25 - 12%

Sudden Cardiac Death and Congestive Heart Failure: Diagnosis and Treatment Proceedings of the Symposium on New Drugs and Devices, held at Philadelphia, PA, October 26 and 27, 1982

12% sparen

144,99 € UVP 164,99 €

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

30.04.1983

Herausgeber

J. Morganroth + weitere

Verlag

Springer Us

Seitenzahl

302

Maße (L/B/H)

23,4/15,6/1,9 cm

Gewicht

630 g

Auflage

1983 edition

Sprache

Englisch

ISBN

978-0-89838-580-9

Beschreibung

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

30.04.1983

Herausgeber

Verlag

Springer Us

Seitenzahl

302

Maße (L/B/H)

23,4/15,6/1,9 cm

Gewicht

630 g

Auflage

1983 edition

Sprache

Englisch

ISBN

978-0-89838-580-9

Herstelleradresse

Libri GmbH
Europaallee 1
36244 Bad Hersfeld
DE

Email: gpsr@libri.de

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)

  • Produktbild: Sudden Cardiac Death and Congestive Heart Failure: Diagnosis and Treatment
  • Produktbild: Sudden Cardiac Death and Congestive Heart Failure: Diagnosis and Treatment
  • New Antiarrhythmic Agents: Basic Considerations.- Do animal models predict results in man?.- Application of pharmacologic principles in the evaluation of new antiarrhythmic agents.- Characterization of antiarrhythmic drugs.- Panel Discussion: New antiarrhythmic agents: basic considerations.- Efficacy Models For Patients With Chronic Ventricular Arrhythmias.- How should ventricular arrhythmias be classified and which patients should be treated?.- Study design for patients with chronic ventricular ectopy: determination of efficacy and tolerance.- Chronic tolerance to antiarrhythmic therapy How to handle emergency drug requests.- Panel Discussion: Efficacy models for patients with chronic ventricular arrhythmias.- Efficacy Models: Acute Ventricular Arrhythmias.- The value of electrophysiologic testing in predicting long-term efficacy of antiarrhythmic drugs in patients with life-threatening ventricular arrhythmias.- Efficacy models: acute ventricular arrhythmias.- A look to the future: outpatient placebo controlled trials of antiarrhythmic drug efficacy in patients with life-threatening ventricular arrhythmias.- Panel Discussion: Efficacy models: acute ventricular arrhythmias.- Sudden Death: Can it Now be Used as an Endpoint?.- Protocol design for sudden death prevention.- Do beta blockers prevent sudden cardiac death?.- Does non beta-blocking antiarrhythmic therapy prevent sudden cardiac death?.- Current problems in the evaluation and approval of new antiarrhythmic agents.- Panel Discussion: Sudden death: can it now be used as an endpoint?.- New Devices: Pacemakers in the Treatment of Arrhythmias and Prevention of Sudden Cardiac Death.- New devices: pacemakers in the treatment of arrhythmias and prevention of sudden cardiac death.- Transvenous cardioversion to treat tachyarrhythmias.- The role of permanently implanted pacemakers in the therapy of recurrent tachyarrhythmias.- Clinical evaluation of an implantable automatic cardioverter defibrillator.- Evaluation of devices for the prevention of sudden death: study design for safety and efficacy of the devices.- New device approval by the Food and Drug Administration.- Panel Discussion: New devices: pacemakers in the treatment of arrhythmias and prevention of sudden cardiac death.- New Cardiac Inotropic Agents.- Pharmacologic principles in the use of new inotropic agents.- The clinical assessment of A inotropic drugs.- Panel Discussion: New cardiac inotropic agents.- Conclusion: Remarks by Arthur Hull Hayes, Jr., Commissioner of Food and Drugs.- List of Participants.